›Portfolio Companies

Past, Present and Future Leaders

InterWest is proud and privileged to partner with visionary management teams who are shaping the future of Information Technology and Healthcare. The companies they have started are vital parts of the portfolio of industry-leading startups that InterWest has helped over the last four decades.

Our Companies

Early stage IT and Healthcare Investing




Mon, 06/11/2012 - 10:58 -- admin

Neuronetics is a medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. It is the first and only company to have a non-systemic and non-invasive depression treatment cleared by the FDA for patients who have not benefited from prior antidepressant treatment.


Mon, 06/11/2012 - 10:56 -- admin

Nanostim is developing a self-contained leadless cardiac pacemaker system to eliminate the leads and surgical pocket required by conventional pacemakers, thereby removing the associated complications of infection and mechanical lead failure. The Nanostim approach changes pacemaker therapy delivery from a surgical procedure to a less-invasive, simplified catheter-based procedure.


Mon, 06/11/2012 - 10:55 -- admin

Microfabrica is a developer of micro- and millimeter-scale devices and systems. Its breakthrough process and materials enable the development of Ultra-High Precision™ Parts, SubAssemblies and 3D MicroMachines, which are used in a variety of medical-device, semiconductor-test and aerospace applications.


Mon, 06/11/2012 - 10:52 -- admin

Founded in 2000, MacroGenics (MGNX) is a biotechnology company headquartered in Rockville, Maryland that focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases. The company's proprietary Fc engineering technology offers ways of improving antibody function, such as enhancing its ability to eliminate cancer cells, cells that contribute to autoimmune disorders, or those infected with certain pathogens.


Mon, 06/11/2012 - 10:51 -- admin

Lycera is a biopharmaceutical company pioneering innovative approaches to the discovery and development of oral medicines for treating autoimmune diseases. The company is targeting novel pathways to develop new classes of selective, oral immunomodulators for the treatment of patients with diseases such as rheumatoid arthritis, multiple sclerosis, psoriasis and inflammatory bowel disease.


Mon, 06/11/2012 - 10:48 -- admin

As surgery has rapidly become less invasive, it has driven the need for better illumination and surgical tools. Invuity’s Eigr technology utilizes unique optical structures to deliver light - uniformly and efficiently - to even the smallest surgical fields. This proprietary technology is integrated into surgical tools, providing unprecedented visualization into areas where surgeons struggle to see.


Mon, 06/11/2012 - 10:44 -- admin

Gynesonics is developing a minimally-invasive, uterine-sparing treatment for fibroid tumors. It is an ultrasound-guided needle ablation device designed for in-office use by the gynecologist.


Mon, 06/11/2012 - 10:43 -- admin

Founded in 2001 and headquartered in Orange County, California, Glaukos is an ophthalmic medical device company that is committed to transforming the management of open-angle glaucoma. The company is well capitalized to develop and commercialize innovative treatment technologies for glaucoma specialists and general, comprehensive ophthalmic surgeons. Through rigorous scientific and clinical research, Glaukos is developing a portfolio of minimally-invasive micro-bypass stents to improve upon the safety and efficacy outcomes of surgical implant procedures.


Mon, 06/11/2012 - 10:39 -- admin

Fluidigm is a biotech tools company that creates microfluidic-based chips and instrumentation for biological research. Its technology enables the rapid, efficient, highly parallel, and reproducible analysis of tens to hundreds of genetic markers across hundreds or thousands of DNA samples in hours instead of days or weeks. The company went public in 2011.


Mon, 06/11/2012 - 10:36 -- admin

Epocrates enables health care providers to deliver better patient care by providing access to reliable clinical information through the use of mobile technology to support clinical decisions at the point of care. More than one in four U.S. physicians and nearly one in two medical students actively use Epocrates' mobile and web-based products. The company had an initial public offering in 2007.


Subscribe to RSS - Healthcare
Facebook Google+ Twitter Email LinkedIn Share